Pharmaceutical

IDE-161 by Ideaya Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval

IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Metastatic Ovarian Cancer.

Dec 22, 2023 - 18:00
IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Metastatic Ovarian Cancer.
Read the original article

Tags:

Previous Article

Runimotamab by Genentech USA for Solid Tumor: Likelihood of Approval

Next Article

Iruplinalkib by Qilu Pharmaceutical for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

UK takes measures to tackle Utrogestan hormone replacement shortage

UK takes measures to tackle Utrogestan hormone replacem...

May 22, 2023

Deka Biosciences secures $20m to advance product pipeline

Deka Biosciences secures $20m to advance product pipeline

Sep 29, 2023

Cancer drug shortage eases slightly, but it’s still ‘living from paycheck to paycheck’

Cancer drug shortage eases slightly, but it’s still ‘li...

Oct 6, 2023